Induction of autoimmunity by pristane and other naturally occurring hydrocarbons

Trends in Immunology

Volumn 30, Issue 9, 2009, Pages 455-464

  Reeves, Westley H ^a   Lee, Pui Y ^a   Weinstein, Jason S ^a   Satoh, Minoru ^a   Lu, Li ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; COLLAGEN TYPE 2; FREUND ADJUVANT; GAMMA INTERFERON; HEXADECANE; HYDROCARBON; INTERFERON; PRISTANE; RHEUMATOID FACTOR; SQUALENE;

ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTHRITIS; AUTOIMMUNITY; B LYMPHOCYTE; CARCINOGENESIS; CELL MATURATION; GLOMERULONEPHRITIS; HUMAN; INTERFERON PRODUCTION; LYMPHOID TISSUE; MONOCYTE; NONHUMAN; PROTEIN EXPRESSION; PULMONARY VASCULITIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOANTIBODIES; DISEASE MODELS, ANIMAL; HUMANS; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; SIGNAL TRANSDUCTION; SNRNP CORE PROTEINS; TERPENES;

EID: 68949183471     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2009.06.003     Document Type: Review

References (93)

1. Avigan J., and Blumer M. On the origin of pristane in marine organisms. J. Lipid Res. 9 (1968) 350-352
2. Grob K., et al. Mineral oil material in canned foods. Food Additives & Contaminants 14 (1997) 83-88
3. Castle L., et al. Migration of mineral hydrocarbons into foods. 4. Waxed paper for packaging dry goods including bread, confectionary and for domestic use including microwave cooking. Food Additives and Contaminants 11 (1994) 79-89
4. Heimbach J.T., et al. Dietary exposures to mineral hydrocarbons from food-use applications in the United States. Food Chem. Toxicol. 40 (2002) 555-571
5. Cruickshank B. Follicular (mineral oil) lipidosis: I. Epidemiologic studies of involvement of the spleen. Hum. Pathol 15 (1984) 724-730
6. Cruickshank B., and Thomas M.J. Mineral oil (follicular) lipidosis: II. histologic studies of spleen, liver, lymph nodes, and bone marrow. Hum. Pathol 15 (1984) 731-737
7. Wanless I.R., and Geddie W.R. Mineral oil lipogranulomata in liver and spleen: a study of 465 autopsies. Arch. Pathol. Lab. Med. 109 (1985) 283-286
8. Potter M., and Boyce C.R. Induction of plasma-cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature (Lond.) 193 (1962) 1086-1087
9. Anderson P.N., and Potter M. Induction of plasma cell tumours in BALB/c mice with 2,6,10,14-tetramethylpentadecane (pristane). Nature (Lond.) 222 (1969) 994-995
10. Potter M., and Wiener F. Plasmacytomagenesis in mice: model of neoplastic development dependent upon chromosomal translocations. Carcinogenesis 13 (1992) 1681-1697
11. Whitehouse M.W., et al. Freund's adjuvants: relationship of arthritogenicity and adjuvanticity in rats to vehicle composition. Immunology 27 (1974) 311-330
12. Valentino M., et al. Hand injuries due to high-pressure injection devices for painting in shipyards: circumstances, management, and outcome in twelve patients. Am. J. Ind. Med. 43 (2003) 539-542
13. Spickard A. Exogenous lipoid pneumonia. Arch. Intern. Med. 154 (1994) 686-692
14. Dincsoy H.P., et al. Lipogranulomas in non-fatty human livers: a mineral oil induced environmental disease. Am. J. Clin. Pathol. 78 (1982) 35-41
15. Sverdrup B., et al. Association between occupational exposure to mineral oil and rheumatoid arthritis: results from the Swedish EIRA case-control study. Arthritis Res. Ther. 7 (2005) R1296-R1303
16. Dahlgren J., et al. Cluster of systemic lupus erythematosus (SLE) associated with an oil field waste site: a cross sectional study. Environ. Health 6 (2007) 8
17. Koppang E.O., et al. Vaccination-induced systemic autoimmunity in farmed Atlantic salmon. J. Immunol. 181 (2008) 4807-4814
18. Potter M., and Wax J.S. Genetics of susceptibility to pristane-induced plasmacytomas in BALB/cAn: Reduced susceptibility in BALB/cJ with a brief description of pristane-induced arthritis. J. Immunol. 127 (1981) 1591-1595
19. Satoh M., and Reeves W.H. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J. Exp. Med. 180 (1994) 2341-2346
20. Satoh M., et al. Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. Clin. Exp. Immunol. 121 (2000) 399-405
21. Wooley P.H., et al. Pristane-induced arthritis. The immunologic and genetic features of an experimental murine model of autoimmune disease. Arthritis Rheum. 32 (1989) 1022-1030
22. Satoh M., et al. Antinuclear antibody production and immune complex glomerulonephritis in BALB/c mice treated with pristane. Proc. Natl. Acad. Sci. USA 92 (1995) 10934-10938
23. Satoh M., et al. Induction of lupus autoantibodies by adjuvants. J. Autoimm. 21 (2003) 1-9
24. Kuroda Y., et al. Distinctive patterns of autoimmune response induced by different types of mineral oil. Toxicol. Sci. 78 (2004) 222-228
25. Mizutani A., et al. Pristane-induced autoimmunity in germ-free mice. Clin. Immunol. 114 (2005) 110-118
26. Craft J. Tolerance to self antigens in normal and lupus mice: the role of autoantigen specific B and T cell responses in autoantibody production. Rheumatology in Europe Supplement 2 (1995) 11-20
27. Jakymiw A., et al. Autoimmune targeting of key components of RNA interference. Arthritis Res. Ther. 8 (2006) R87
28. Richards H.B., et al. Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice. Clin. Exp. Immunol. 115 (1999) 547-553
29. Nacionales, D.C. et al. (2009) B cell proliferation, somatic hypermutation, and class switching in ectopic lymphoid tissue in murine lupus. J. Immunol. In Press
30. Levitt N.G., et al. Pristane induced arthritis in mice. IV. Immunotherapy with monoclonal antibodies directed against lymphocyte subsets. J. Rheumatol 19 (1992) 1342-1347
31. Richards H.B., et al. IL-6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J. Exp. Med 188 (1998) 985-990
32. Nacionales D.C., et al. Deficiency of the Type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 56 (2007) 3770-3783
33. Mitani Y., et al. Cross talk of the interferon-alpha/beta signalling complex with gp130 for effective interleukin-6 signalling. Genes Cells 6 (2001) 631-640
34. Levy D.E., et al. Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF3. EMBO J 9 (1990) 1105-1111
35. Kuroda Y., et al. Induction of lupus-related specific autoantibodies by non-specific inflammation caused by an intraperitoneal injection of n-hexadecane in BALB/c mice. Toxicology 218 (2006) 186-196
36. Smith D.L., et al. A female preponderance for chemically induced lupus in SJL/J mice. Clin. Immunol. 122 (2007) 101-107
37. Beech J.T., and Thompson S.J. Anti-tumour necrosis factor therapy ameliorates joint disease in a chronic model of inflammatory arthritis. Br. J. Rheumatol. 36 (1997) 1129
38. Satoh M., et al. Autoantibodies to ribosomal P antigens with immune complex glomerulonephritis in SJL mice treated with pristane. J. Immunol. 157 (1996) 3200-3206
39. Chowdhary V.R., et al. Characterization of haemorrhagic pulmonary capillaritis: another manifestation of Pristane-induced lupus. Rheumatology (Oxford) 46 (2007) 1405-1410
40. Richards H.B., et al. Interferon-gamma promotes lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int. 60 (2001) 2173-2180
41. Calvani N., et al. Nephritogenic autoantibodies but absence of nephritis in IL-12p35-deficient mice with pristane-induced lupus. Kidney Int. 64 (2003) 897-905
42. Clynes R., et al. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science (Wash. D. C.) 279 (1998) 1052-1054
43. Peterson K.S., et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J. Clin. Invest 113 (2004) 1722-1733
44. Kulkarni O., et al. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J. Am. Soc. Nephrol. 18 (2007) 2350-2358
45. Satoh M., et al. Fas and Fas ligand mutations inhibit autoantibody production in pristane-induced lupus. J. Immunol. 165 (2000) 1036-1043
46. Vingsbo-Lundberg C., et al. Genetic control of arthritis onset, severity and chronicity in a model for rheumatoid arthritis in rats. Nat. Genet. 20 (1998) 401-404
47. Ioannou Y., and Isenberg D.A. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 43 (2000) 1431-1442
48. Ronnblom L.E., et al. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann. Intern. Med. 115 (1991) 178-183
49. Pestka S., et al. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202 (2004) 8-32
50. Hooks J.J., et al. Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med. 301 (1979) 5-8
51. Baechler E.C., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U. S. A 100 (2003) 2610-2615
52. Bennett L., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197 (2003) 711-723
53. Feng X., et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 54 (2006) 2951-2962
54. Kirou K.A., et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52 (2005) 1491-1503
55. Zhuang H., et al. Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clin. Immunol. 117 (2005) 238-250
56. Mathian A., et al. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J. Immunol 174 (2005) 2499-2506
57. Santiago-Raber M.L., et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197 (2003) 777-788
58. Jorgensen T.N., et al. Type I interferon signaling is involved in the spontaneous development of lupus-like disease in B6.Nba2 and (B6.Nba2 x NZW)F(1) mice. Genes Immun 8 (2007) 653-662
59. Banchereau J., and Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25 (2006) 383-392
60. Nacionales D.C., et al. Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14 tetramethylpentadecane (pristane). Am. J. Pathol 168 (2006) 1227-1240
61. Thibault D.L., et al. IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J. Clin. Invest 118 (2008) 1417-1426
62. Lee P.Y., et al. A novel type I IFN-producing cell subset in murine lupus. J. Immunol. 180 (2008) 5101-5108
63. Lee P.Y., et al. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J. Exp. Med. 205 (2008) 2995-3006
64. Bave U., et al. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J. Immunol 171 (2003) 3296-3302
65. Sunderkotter C., et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J. Immunol. 172 (2004) 4410-4417
66. Benech P., et al. 3′ end structure of the human (2′-5′) oligo A synthetase gene: prediction of two distinct proteins with cell type-specific expression. Nucleic Acids Res. 13 (1985) 1267-1281
67. Tacke F., et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Invest 117 (2007) 185-194
68. Swirski F.K., et al. Ly-6C monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J. Clin. Invest 117 (2007) 195-205
69. Drevets D.A., et al. The Ly-6Chigh monocyte subpopulation transports Listeria monocytogenes into the brain during systemic infection of mice. J. Immunol. 172 (2004) 4418-4424
70. Kawai T., and Akira S. Innate immune recognition of viral infection. Nat. Immunol. 7 (2006) 131-137
71. Means T.K., et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest 115 (2005) 407-417
72. Savarese E., et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 107 (2006) 3229-3234
73. Vollmer J., et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med 202 (2005) 1575-1585
74. Savarese E., et al. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum. 58 (2008) 1107-1115
75. Pisitkun P., et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science (Wash. D. C.) 312 (2006) 1669-1672
76. Herrmann M., et al. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum. 41 (1998) 1241-1250
77. Vallin H., et al. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J. Immunol. 163 (1999) 6306-6313
78. Barrat F.J., et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202 (2005) 1131-1139
79. Clynes R., et al. Modulation of the immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors. Clin. Exp. Immunol. 141 (2005) 230-237
80. Bly J.E., et al. Pristane induced changes in rat lymphocyte membrane fluidity. Cancer Biochem. Biophys. 11 (1990) 145-154
81. Kratz A., et al. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J. Exp. Med. 183 (1996) 1461-1472
82. Aloisi F., and Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol. 6 (2006) 205-217
83. Schroder A.E., et al. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc. Natl. Acad. Sci. U. S. A 93 (1996) 221-225
84. Gause A., et al. The B lymphocyte in rheumatoid arthritis: analysis of rearranged V kappa genes from B cells infiltrating the synovial membrane. Eur. J. Immunol. 25 (1995) 2775-2782
85. William J., et al. Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science (Wash. D. C.) 297 (2002) 2066-2070
86. Horsfall A.C., et al. Autoantibody synthesis in salivary glands of Sjogren's syndrome patients. J. Autoimmun. 2 (1989) 559-568
87. Randen I., et al. The identification of germinal centres and follicular dendritic cell networks in rheumatoid synovial tissue. Scand. J. Immunol. 41 (1995) 481-486
88. Jego G., et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19 (2003) 225-234
89. Leak L.V., et al. Response of the peritoneal mesothelium to the mineral oil, pristane. Curr. Top. Microbiol. Immunol. 122 (1985) 221-233
90. Weinstein J.S., et al. Colocalization of antigen-specific B and T cells within ectopic lymphoid tissue following immunization with exogenous antigen. J. Immunol. 181 (2008) 3259-3267
91. Klein U., and Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat. Rev. Immunol. 8 (2008) 22-33
92. Ettinger R., et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J. Immunol. 175 (2005) 7867-7879
93. Cassese G., et al. Inflamed kidneys of NZB/W mice are a major site for the homeostasis of plasma cells. Eur. J. Immunol. 31 (2001) 2726-2732